Skip to main content
. 2018 Jan 23;2018:9727240. doi: 10.1155/2018/9727240

Table 5.

Safety parameters among ischemic stroke patients (phase III study).

Aspirin + placebo Aspirin + BJIKT P
Baseline Net change from baseline Baseline Net change from baseline
Liver function
 AST 24.7 ± 4.9 1.8 ± 5.9 25.2 ± 5.4 2.0 ± 6.3 NS
 ALT 23.5 ± 11.7 1.2 ± 8.6 21.4 ± 8.1 1.6 ± 6.2 NS
 GGT 29.6 ± 12.5 0.0 ± 4.4 29.1 ± 16.2 0.1 ± 4.9 NS
 T-bil 0.6 ± 0.2 −0.0 ± 0.1 0.6 ± 0.2 0.0 ± 0.1 NS
 ALP 78.1 ± 16.9 0.7 ± 7.4 68.5 ± 15.8 0.8 ± 6.2 NS
 Protein 7.6 ± 0.5 0.0 ± 0.4 7.4 ± 0.4 −0.0 ± 0.4 NS
 Albumin 4.4 ± 0.1 −0.0 ± 0.2 4.3 ± 0.2 −0.0 ± 0.1 NS
Kidney function
 BUN 15.6 ± 2.5 −1.8 ± 4.1 16.6 ± 5.3 −2.3 ± 4.7 NS
 Cr 0.7 ± 0.1 −0.0 ± 0.0 0.8 ± 0.4 −0.0 ± 0.0 NS
Adverse effects
 Indigestion 1 1 NS
 Diarrhea 1 0 NS

BJIKT: Bojungikki-tang, AST: aspartate aminotransferase, ALT: alanine aminotransferase, GGT: gamma-glutamyl transferase, T-bil: total bilirubin, ALP: alkaline phosphatase, and BUN: blood urea nitrogen.